COVID-19 and the male susceptibility : the role of ACE2, TMPRSS2 and the androgen receptor
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
COVID-19 is the pandemic that hit the world starting December 2019. Recent studies and international statistics have shown an increased prevalence, morbidity as well as mortality of this disease in male patients compared to female patients. The aim of this brief communication is to describe the pathophysiology of this sex-discrepancy, based on the infectivity mechanism of the coronavirus including the Angiotensin-Converting Enzyme 2 (ACE2), the Type II transmembrane Serine Protease (TMPRSS2), and the androgen receptor. This could help understand the susceptibility of urological patients, especially those receiving androgen deprivation therapy for prostate cancer, and testosterone replacement therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 30(2020), 10 vom: 15. Sept., Seite 484-487 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mjaess, G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.10.2020 Date Revised 11.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.purol.2020.05.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311980821 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311980821 | ||
| 003 | DE-627 | ||
| 005 | 20231225143424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.purol.2020.05.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311980821 | ||
| 035 | |a (NLM)32620366 | ||
| 035 | |a (PII)S1166-7087(20)30186-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mjaess, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and the male susceptibility |b the role of ACE2, TMPRSS2 and the androgen receptor |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2020 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a COVID-19 is the pandemic that hit the world starting December 2019. Recent studies and international statistics have shown an increased prevalence, morbidity as well as mortality of this disease in male patients compared to female patients. The aim of this brief communication is to describe the pathophysiology of this sex-discrepancy, based on the infectivity mechanism of the coronavirus including the Angiotensin-Converting Enzyme 2 (ACE2), the Type II transmembrane Serine Protease (TMPRSS2), and the androgen receptor. This could help understand the susceptibility of urological patients, especially those receiving androgen deprivation therapy for prostate cancer, and testosterone replacement therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Angiotensin-Converting Enzyme 2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Enzyme de conversion de l’angiotensine 2 | |
| 650 | 4 | |a Récepteur aux androgènes | |
| 650 | 4 | |a Sérine protéase transmembranaire 2 | |
| 650 | 4 | |a Type II Transmembrane Serine Protease | |
| 650 | 4 | |a androgen receptor | |
| 650 | 7 | |a AR protein, human |2 NLM | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Androgens |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
| 650 | 7 | |a Receptors, Androgen |2 NLM | |
| 650 | 7 | |a Receptors, Virus |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a Peptidyl-Dipeptidase A |2 NLM | |
| 650 | 7 | |a EC 3.4.15.1 |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Serine Endopeptidases |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 650 | 7 | |a TMPRSS2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 700 | 1 | |a Karam, A |e verfasserin |4 aut | |
| 700 | 1 | |a Aoun, F |e verfasserin |4 aut | |
| 700 | 1 | |a Albisinni, S |e verfasserin |4 aut | |
| 700 | 1 | |a Roumeguère, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie |d 1997 |g 30(2020), 10 vom: 15. Sept., Seite 484-487 |w (DE-627)NLM012649481 |x 1166-7087 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2020 |g number:10 |g day:15 |g month:09 |g pages:484-487 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.purol.2020.05.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2020 |e 10 |b 15 |c 09 |h 484-487 | ||